News

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.
A new shot prevents HIV—and breathes new life into a stagnant biotech
Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...
Long-lasting HIV prevention shot heads toward approval
A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.
Stocktwits on MSN8d
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance
Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...
Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"
NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...
KFF Health News2d
Gilead Pins Its Hopes On Breakthrough Twice-Yearly HIV Prevention Shot
The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...
2 Reasons to Like GILD (and 1 Not So Much)
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...
Trump administration ending multiple HIV vaccine studies, scientists and officials say
The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...
CSR Wire2d
Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of “The Centrifuge Sessions”
In our latest episode of The Centrifuge Sessions, Magdeleine Hung, Director of Protein Therapeutics, shares insights on our pioneering work in HIV. Gilead Sciences Gilead Sciences, Inc. is a ...